### Budesonide + formoterol

**Indication**  
Asthma  
*ICD11 code: CA23*

**INN**  
Budesonide + formoterol

**Medicine type**  
Chemical agent

**List type**  
Core

**Formulations**  
Respiratory > Inhalation > dry powder: 100 µg + 6 µg per dose ; 200 µg + 6 µg per dose

**EML status history**  
First added in 2017 *(TRS 1006)*  
Changed in 2021 *(TRS 1035)*

**Sex**  
All

**Age**  
Adolescents and adults

**Therapeutic alternatives**  
- budesonide + salmeterol (ATC codes: R03AK12)  
- beclometasone + formoterol (ATC codes: R03AK08)  
- mometasone + formoterol (ATC codes: R03AK09)  
- fluticasone + formoterol (ATC codes: R03AK11)  
- fluticasone furoate + vilanterol (ATC codes: R03AK10)

**Patent information**  
Patents have expired in most jurisdictions  
Read more about patents.

**Wikipedia**  
[Budesonide + formoterol](https://en.wikipedia.org/wiki/Budesonide_formoterol)

**DrugBank**  
[Budesonide](https://www.drugbank.ca/drugs/DB01916)  
[Formoterol](https://www.drugbank.ca/drugs/DB01920)

### Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended the following be specified as therapeutic alternatives under the square box listing for budesonide + formoterol for treatment of asthma on the EML:  
- beclometasone + formoterol, budesonide + salmeterol, fluticasone + formoterol, fluticasone furoate + vilanterol, and mometasone + formoterol.